ArticleFrontiers in oncology2025
ASPHD1 Is a tumor-suppressive and prognostic marker in glioma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioma is a highly aggressive primary brain tumor. To identify novel prognostic biomolecules and potential therapeutic targets, we investigated Aspartate betahydroxylase domain-containing protein 1 (ASPHD1), encoded by the Methods: We assessed its expression and prognostic value using transcriptomic data from the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Chinese Glioma Genome Atlas (CGGA). Co-expressed gene enrichment and DNA-methylation analyses were performed, and associations between ASPHD1 expression and overall survival (OS) were evaluated. Gene Ontology and KEGG analyses of ASPHD1 coexpressed genes indicated enrichment in synaptic signaling, ion-channel activity, and calcium-signaling pathways, suggesting a link with neuronal and synaptic function. Results: ASPHD1 expression showed a pronounced inverse correlation with WHO grade, and higher ASPHD1 expression was associated with prolonged OS; multivariable Cox models identified low ASPHD1 as an independent adverse prognostic factor. Pan-cancer analysis further revealed that higher ASPHD1 expression was associated with longer OS in skin cutaneous melanoma (SKCM), uveal melanoma (UVM), and mesothelioma (MESO). In glioma cell lines, ASPHD1 overexpression suppressed proliferation, migration, and invasion in vitro, and inhibited tumor growth in a subcutaneous U87 xenograft model. ASPHD1 overexpression also upregulated neuronal differentiation-related genes, produced more negative resting membrane potentials on whole-cell patch-clamp recordings, enhanced depolarization-evoked Ca Discussion: Together, these findings identify ASPHD1 as a favorable prognostic biomarker in glioma and suggest that high ASPHD1 expression restrains glioma progression while promoting neuron-like differentiation of glioma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.